ArticleBMC medical research methodology2026
AI-derived constrained conditional model for screening marker genes through integrated high-throughput transcriptome big data.
Article in BMC medical research methodology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Currently, a large volume of high-throughput transcriptome data are accessible through various public databases. This brings urgent need to integrate transcriptome data sourced from numerous independent studies to extract common characteristics to precisely address specific research questions. Referring to this, we innovatively designed a model framework that leverages integrated transcriptome data with declarative constraints. Here the constraint is used to incorporate the AI-derived prior knowledge (genes in certain biological pathways, functions or user-specified terms) into the model and drive the model prediction/decision to satisfy these constraints. Distinguishing from existing models or methods, this framework implies tailed non-parametric bootstrapping algorithm to generate millions of samples of p-value of independent analyses to avoid the normal procedure of integrating data with distinct distribution styles and difference from users’ requirements. The model was applied in 5 tumor and 5 non-tumor case studies using 81 downloaded transcriptome datasets with 10,647 samples. High percentage of the selected genes were accordant with published work, co-occurrence results and gene ontology results. Experimental validations including transwell invasion/migration confirmed the identified genes associated with cancer progression in prostate, liver, and endometrial cancer case studies. Therefore our model was effective in extracting marker genes under user-specified conditions and were possessing significance in further understanding specified situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.